Progress, Potential, and Possibilities Podcast / Show

Send us Fan MailDr. David Feinberg, M.D., is Chairman of Oracle Health ( https://www.oracle.com/health/ ), where he and his team are committed to making healthcare more accessible, affordable and equitable, building an open healthcare platform with intelligent tools for data-driven, human-centric healthcare experiences to connect consumers, healthcare providers, payers, and public health and life sciences organizations.Dr. Feinberg’s work advances thought leadership and strategy related to unleashing the healing power of data through an open and connected healthcare ecosystem. Previously, Dr. Feinberg served as president and CEO of Cerner, now Oracle Health, where he led teams delivering tools and technology to execute on this strategy of improving the patient and caregiver experience. As a pediatric psychiatrist, Dr. Feinberg built his early career around helping children and families. He served as president and CEO of both UCLA Health and Geisinger Health prior to assuming leadership of Google Health in early 2019. Dr. Feinberg began his career at UCLA, researching and publishing in the areas of addiction and attention deficit hyperactivity disorder. He took on additional leadership responsibilities, including becoming the Medical Director of the Resnick Neuropsychiatric Hospital. Dr. Feinberg earned his M.D. from Chicago Medical School in 1989, finishing at the top of his class and is a member of the Alpha Omega Alpha Medical Honor Society. He also holds an economics degree from the University of California-Berkeley and an MBA from Pepperdine University.#DavidFeinberg #OracleHealth #Oracle #LarryEllison #GoogleHealth #GeisingerHealth #UCLAHealth #ElectronicHealthRecords #EHR #ClinicalDigitalAssistant #PediatricPsychiatry #SocialDeterminantsOfHealth #ArtificalIntelligence #MentalHealth #AgingInPlace #DigitalHealth #FoodPharmacy #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us Fan MailRobert Stone is the CEO of City of Hope ( https://www.cityofhope.org/robert-stone ), a premier cancer research and treatment center dedicated to innovation in biomedical science and the delivery of compassionate, world-class patient care. A seasoned health care executive, he has served in a number of strategic decision-making roles since he joined City of Hope in 1996, culminating with his appointment as president in 2012, CEO in 2014, and as the Helen and Morgan Chu Chief Executive Officer Distinguished Chair in 2021.Mr. Stone has J.D., University of Chicago Law School, Chicago, IL.Mr. Stone’s strategic acumen, empathy and visionary leadership have driven City of Hope’s rapid evolution. As an independent institution dedicated to advancing the fight against cancer and diabetes, City of Hope is accelerating opportunities for high-impact discovery and ensuring that patients around the world have access to the most advanced therapies. Recent examples include a groundbreaking alliance in precision medicine with the Translational Genomics Research Institute (TGen), a leader in genomic analysis and bioinformatics; leadership in CAR T cell therapy research and therapy; and an innovative program to offer cancer support services to the employees of some of American’s largest employers, regardless of geography.Dr. Marcel van den Brink, M.D., Ph.D.( https://www.cityofhope.org/marcel-van-den-brink ), is President of City of Hope Cancer Center, main campus in Los Angeles, and National Medical Center, chief physician executive and the Deana and Steve Campbell Chief Physician Executive Distinguished Chair, and is a globally recognized leader in the basic and translational science of bone marrow transplantation (BMT), the microbiome and cancer immunotherapy.  His specialties include immune reconstitution and graft-versus-host disease — side effects many BMT patients experience — as well as the impact of the microbiome on immunotherapy for cancer. A researcher who has opened new fields of investigation and improved patient outcomes, Dr. Van den Brink has pursued innovative ways to improve and optimize BMT, developing strategies to make the process less toxic and lower the rate of recurrence. Throughout his career, he has maintained an intense focus on converting scientific discoveries in his laboratory into better therapies for patients around the world.Dr. Van den Brink joined City of Hope in part because of their shared commitment to advancing the frontiers of cancer care and research. He is known for his inclusive approach to leadership and his devotion to providing junior faculty colleagues with mentorship and career development opportunities.A recipient of numerous national and international awards, Dr. Van den Brink is a member of the Royal Netherlands Academy of Arts and Sciences. Among many leadership roles, he serves as vice chair of the board for Deutsche Knochenmark Stiftung, a global donor registration that facilitates 40% of all unrelated allogenic blood stem cell donations worldwide.Dr. Van den Brink has a Ph.D., Medicine (Immunology), and M.D., Cum Laude, University of Leiden, The Netherlands, completed a postdoctoral fellowship at the Pittsburgh Cancer Institute in Pittsburgh, PA and residency at Duke University Medical Center in Durham, NC. #Cancer #Oncology #CityOfHope #RobertStone #MarcelVanDenBrink #Microbiome #Immunotherapy #CarT #Thymus #ThymicInvolution #Regeneration #BoneMarrowTransplantation #TranslationalGenomicsResearchInstitute #PrecisionMedicine #GraftVersusHostDisease #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us Fan MailDr. Sudip Parikh, Ph.D. ( https://www.aaas.org/person/sudip-parikh ), is the Chief Executive Officer of the American Association for the Advancement of Science (AAAS) and Executive Publisher of the Science family of journals and has spent the last two decades at the nexus of science, policy, and business.Prior to joining AAAS, Dr. Parikh was senior vice president and managing director at Drug Information Association (DIA Global), a neutral, multidisciplinary organization for healthcare product development where he led strategy in the Americas and oversaw DIA programs that catalyzed progress globally toward novel regulatory frameworks for advanced therapies.Prior to DIA, Dr. Parikh was a vice president at Battelle, a multibillion-dollar research and development organization, where he led two business units with over 500 scientific, technical, and computing experts performing basic and applied research, developing medicines and healthcare devices, developing agricultural products, and creating advanced analytics and artificial intelligence applications to improve human health.From 2001 to 2009, Dr. Parikh served as science advisor to the Republican leadership of the U.S. Senate Appropriations Committee, where he was responsible for negotiating budgets for the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Agency for Healthcare Research and Quality, Biomedical Advanced Research and Development Authority (BARDA), and other scientific and health agencies.As a key legislative liaison to the research and development ecosystem, Dr. Parikh was on the frontlines of many science policy issues debated during that time, including embryonic stem cell research, cloning, disease surveillance, bioterrorism, cyber security, and doubling the NIH budget.An active member of the scientific advocacy community, Dr. Parikh serves as a board member and officer for several impactful organizations, including Research!America ( https://www.researchamerica.org/ ), which he has chaired since 2023, Friends of Cancer Research, and ACT for NIH.  He also serves as co-chair of the Science and Technology Action Committee ( https://sciencetechaction.org/ ), Science CEO Group, and the Coalition for Trust in Health and Science ( https://trustinhealthandscience.org/ ).  He is also a member of the Board of Life Sciences of the U.S. National Academies of Science, Engineering, and Medicine.Dr. Parikh is an elected member of the American Academy of Arts and Sciences and the Council on Foreign Relations. He has also received multiple public service awards, including recognition from the Society for Women’s Health Research, the American Association of Immunologists, the National AIDS Alliance, the Coalition for Health Services Research, and the Juvenile Diabetes Research Foundation.Early in his career, Dr. Parikh was a Presidential Management Intern at the NIH. He was awarded a National Science Foundation Graduate Research Fellowship while earning his Ph.D. in macromolecular structure and chemistry at the Scripps Research Institute in La Jolla, Calif.  There, he used structural biology and biochemistry techniques to probe the mechanisms of DNA repair enzymes.  Dr. Parikh completed undergraduate studies at the University of North Carolina at Chapel Hill, first as a journalism major before switching into materials science. #SudipParikh #AAAS #AmericanAssociationForTheAdvancementOfScience #Science #Policy #Business #DrugInformationAssociation #Battelle #ResearchAmerica  #ScienceAndTechnologyActionCommittee #CoalitionForTrustInHealthAndScience #Appropriations #Congress #ArtificialIntelligence #DrugDevelopment #ProgressPotentialAndPossibilities #IraPastor Support the show

Send us Fan MailDr. Abigail Stevenson is Chief Science Officer (CSO), at Mars ( https://www.mars.com/ ), the multinational manufacturer of confectionery, pet food, and other food products, and a provider of pet care services, where she champions Mars’ involvement in global, cutting-edge science discovery, drives external partnerships with academia, start ups, non-governmental organizations and peers; helps build the pipeline of leading science and technology talent at Mars; and provides leadership of the Mars Science Leadership Team. Dr. Stevenson assumed the CSO role in October 2022 and she also oversees the Mars Advanced Research Institute ( MARI - https://www.mars.com/mari ), which connects Mars with emerging science and technology to spark discoveries with the potential to reinvent the future of its business,  and the Mars Global Food Safety Center ( GFSC - https://gfsc.mars.com/ ), a state-of-the-art research and training facility that sits at the heart of a global network of partners and collaborators tackling the most significant food safety challenges facing the planet today. In her career at Mars, Dr. Stevenson has led significant research outputs, delivering innovative solutions that have delivered significant business value and helped address long-standing food industry challenges. Through her career at Mars she has served in multiple roles with the Waltham Petcare Science Institute, including Head of Science Communications and Engagement; and was Director of the Mars GFSC from 2017 to 2020 before assuming the role of Vice President of MARI in 2020. Dr. Stevenson studied Ecology as an undergraduate at University of Stirling and then went on to do a PhD at University College London in nutrition and health.Interesting Episode Link - COcoa Supplement and Multivitamin Outcomes Study - https://cosmostrial.org/#Mars #AbigailStevenson #Health #Nutrition #Wellness #Cocoa #Cacao #Chocolate #Flavanols  #OralMicrobiome #NaturalBlue #Nutrigenomics #Phytochemicals #MarsAdvancedResearchInstitute #MarsGlobalFoodSafetyCenter #Aging #Longevity  #CocoaSupplementAndMultivitaminOutcomesStudy #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us Fan MailSteve Blank is an Adjunct Professor at Stanford and Co-Founder of the Gordian Knot Center for National Security Innovation (https://gordianknot.stanford.edu/people/steve-blank). He has been described as the Father of Modern Entrepreneurship.Credited with launching the Lean Startup movement and the curriculums for the National Science Foundation Innovation Corps and Hacking for Defense and Diplomacy, Steve has changed how startups are built; how entrepreneurship is taught; how science is commercialized, and how companies and the government innovate.Steve is the author of The Four Steps to the Epiphany and The Startup Owner’s Manual which revolutionized how startups were built. His Harvard Business Review cover story redefined how large companies can innovate at speed.Steve blogs at www.steveblank.com#SteveBlank #NationalSecurity #DepartmentOfDefense #DoD #Entrepreneuship #LeanStartup #NationalScienceFoundation #InnovationCorps #HackingForDefense #IntelligenceCommunity #SpaceX #ElonMusk #DefenseInnovationUnit #VannevarBush #VentureCapital  #PrimeContractors #LockheedMartin #Boeing #GeneralDynamics  #Raytheon #NorthropGrumman #Anduril #Palantir #Stanford #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us Fan MailProfessor Carlos Duarte, Ph.D. is Distinguished Professor, Marine Science, and Executive Director, Coral Research & Development Accelerator Platform ( CORDAP - https://cordap.org/ ), Biological and Environmental Science and Engineering Division, King Abdullah University of Science and Technology ( KAUST - https://www.kaust.edu.sa/en/study/faculty/carlos-duarte ), in Saudi Arabia, as well as Chief Scientist of Oceans2050, OceanUS, and E1Series.  Prior to these roles Professor Duarte was Research Professor with the Spanish National Research Council (CSIC) and Director of the Oceans Institute at The University of Western Australia. He also holds honorary positions at the Arctic Research Center in Aarhus University, Denmark and the Oceans Institute at The University of Western Australia. Professor Duarte’s research focuses on understanding the effects of global change in marine ecosystems and developing nature-based solutions to global challenges, including climate change, and developing evidence-based strategies to rebuild the abundance of marine life by 2050.  Building on his research showing mangroves, seagrasses and salt-marshes to be globally-relevant carbon sinks, Professor Duarte developed, working with different UN agencies, the concept of Blue Carbon, as a nature-based solution to climate change, which has catalyzed their global conservation and restoration.  For the past years, Professor Duarte has also lead efforts to quantify the global role and importance of algal forests.  He has conducted research across all continents and oceans, spanning most of the marine ecosystem types, from inland to near-shore and the deep sea and from microbes to whales, and has a particular focus on the role of seaweed aquaculture as a sustainable solution for multiple challenges. Professor Duarte led the Malaspina 2010 Expedition, including over 700 scientists from 38 institutions from across 18 nations, that sailed the world’s oceans to examine the impacts of global change on ocean ecosystems and explore deep-sea biodiversity. Professor Duarte served as President of the American Society of Limnology and Oceanography between 2007 and 2010. He has published more than 950 scientific papers a and has been ranked within the top 1% Highly-Cited Scientist by Thompson Reuters in all assessments of this rank, as was ranked as the top marine biologist in the world, and recently, the 12th most influential climate scientist in the world (Reuters). He has received many honors, including the G. Evelyn Hutchinson Award from the American Society of Limnology and Oceanography in 2001, the National Science Award of Spain (2007), and the I. Vernadsky Medal of the European Geophysical Union. the Prix d’Excellence by the International Council for the Exploration of the Seas (ICES, 2011), the Carlo Heip award for excellent in Marine Biodiversity (2018), and the Ramon Margalef Ecology Award (2019), and the BBVA Foundation Frontiers of Knowledge Award in Ecology and Conservation Biology (2020).  Professor Duarte earned a bachelor's degree in environmental biology from Autonomous University of Madrid, Spain  and obtained a Ph.D. in limnology from McGill University#Corals #Oceans #Seagrass #BlueCarbon #BlueEconomy #Mangroves #Reefs #KAUST #ClimateChange #CarbonCapture #CarlosDuarte #Aquaculture #SaltwaterAgriculture #KingAbdullahUniversityOfScienceAndTechnology #KSA #SaudiArabia #RedSea #Bioprospecting #Genomics #CraigVenter #CarbonSink #Environment #Biodiversity #COP16 #Limnology  #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast  #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us Fan MailDr. James L. Madara, MD, is CEO and Executive Vice President of the American Medical Association ( https://www.ama-assn.org/about/authors-news-leadership-viewpoints/james-l-madara-md ), the United States' largest physician organization. He also holds the academic title of adjunct professor of pathology at Northwestern University ( https://www.pathology.northwestern.edu/Faculty/profile.html?xid=24099 ).Since taking the reins of the AMA in 2011, Dr. Madara has helped sculpt the organization’s visionary long-term strategic plan. He also serves as Chairman of Health2047 Inc. ( https://health2047.com/ ), the wholly-owned innovation subsidiary of the AMA, created to overcome systemic dysfunction in U.S. health care and located in Silicon Valley. Working closely with the AMA, Health2047 finds, forms and scales transformative health care spinout companies in four fields: chronic care, data utility, radical productivity and health care value. Several companies have been launched to date.Prior to the AMA, Dr. Madara spent the first 22 years of his career at Harvard Medical School, receiving both clinical and research training, serving as a tenured professor, and as director of the NIH-sponsored Harvard Digestive Diseases Center. Following five years as chair of pathology and laboratory medicine at Emory University, Dr. Madara served as dean of both biology and medicine, and then as CEO of the University of Chicago Medical Center, bringing together the university’s biomedical research, teaching and clinical activities. While there he oversaw the renewal of the institution’s biomedical campus and engineered significant new affiliations with community hospitals, teaching hospital systems, community clinics and national research organizations.Dr. Madara also served as senior advisor with Leavitt Partners, an innovative health care consulting and private-equity firm founded by former Health and Human Services Secretary Mike Leavitt.Having published more than 200 original papers and chapters, Dr. Madara has served as editor-in-chief of the American Journal of Pathology and as president of the American Board of Pathology.In addition to Modern Healthcare consistently naming him as one of the nation’s 50 most influential physician executives, as well as one of the nation’s 100 most influential people in health care, Dr. Madara has been recognized with several national and international awards. These include the prestigious MERIT Award from the National Institutes of Health, the Davenport Award for lifetime achievement in gastrointestinal disease from the American Physiological Society, and the Mentoring Award for lifetime achievement from the American Gastroenterological Society.Dr. Madara is an elected member of both the American Society of Clinical Investigation and the Association of American Physicians. He also co-chairs the Value Incentives & Systems Action Collaborative of the National Academy of Medicine (NAM), and is a member of NAM’s Leadership Consortium for Value & Science-Driven Health Care.#JamesMadara #AmericanMedicalAssociation #AMA #Physicians #Pathology #IntestinalEpithelialPathobiology #MedicalSchool #MedicalEducation #HealthEquity #UniversityOfChicago #SocialDeterminantsOfHealth  #NorthwesternUniversity #Health2047 #VentureCapital #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us Fan MailDr. Amal Al-Maani, MD is Director General for Diseases Surveillance and Control at the Ministry of Health of Oman ( https://moh.gov.om/en/hospitals-directorates/directorates-and-centers-at-hq/directorate-general-for-disease-surveillance-and-control/ ), senior consultant in pediatric infectious diseases in the Sultanate, and is the focal point for the Global Antimicrobial Resistance (AMR) Surveillance System (GLASS) and is responsible for Oman national surveillance system for AMR (OMASS) and the national Infection Prevention and Control (IPC) program. Dr. Al-Maani completed her medical degree from Sultan Qaboos University, Oman and passed the London School diploma in tropical Medicine and Hygiene (DTM&H) during her internship period. Followed by her postgraduate training at the University of Toronto, she achieved her fellowship in pediatric infectious diseases from the Royal College of Physicians and Surgeons, Canada. She has the Certificate In Infection Control from the Certification Board of Infection Control & Epidemiology, a certificate in global health from Dalla Lana School of Public Health the Centre for International Health in the University of Toronto (UFT), and the Patient Safety & Quality Improvement certificate from the center for patient safety in UFT.Dr. Al-Maani has participated in many national and International Conferences and presented many papers. She received Dr Susan King Award at the Canadian AMMI conference 2011 and in 2021 the WHA Sasakawa health development award for her work in AMR and IPC. She published many papers in the field of infectious diseases and infection control with a focus on Antimicrobial resistance and emerging resistant pathogens. She had been a co-author in multiple positional statements for the International Society for Infectious Diseases (ISID) group in infection control, including most recently about the Global Antimicrobial Stewardship with a Focus on Low- and Middle-Income Countries and on the Prevention of Clostridioides.#AntimicrobialResistance #AMR #AmalAlMaani #DiseasesSurveillance #MinistryOfHealth #Oman #SultanQaboosUniversity #WHO #WorldHealthOrganization #OneHealth #Antibiotics #Vaccines #TropicalMedicine #Hygiene #VancomycinResistantEnterococcus #MethicillinResistantStaphylococcus #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast  #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us Fan MailMichael J. Burton is the CEO of the Diabetes Research Institute Foundation ( https://diabetesresearch.org/ ), a philanthropic organization which funds the Diabetes Research Institute, one of the largest and most comprehensive research centers dedicated to curing diabetes.A passionate nonprofit executive, Michael has more than 30 years of experience in leading high-impact philanthropic programs and cultivating strategic relationships to secure transformative funding. Prior to assuming the role of CEO at DRIF, Michael advanced the missions of some of the nation’s most dynamic and trusted institutions including Princeton University, The Pew Charitable Trusts and the American Association for Cancer Research (AACR).Michael’s accomplished nonprofit career includes significant contributions in the advancement of cancer research and care, most recently as President and CEO of Gateway for Cancer Research, a Chicago-based nonprofit engaged in funding early phase clinical research, where he began his tenure as Chief Development Officer. Prior to that, Michael served as Chief Development Officer and Executive Director of the Foundation at the AACR, the nation’s oldest and largest organization dedicated to the prevention and cure of all cancers. Michael’s 15 years of experience in the oncology sector also includes leading the development program at Fox Chase Cancer Center as Senior Vice President and Chief Development Officer.Before working in the field of oncology, Michael had a distinguished career in higher education, most notably at the University of Pennsylvania, where he served as Special Assistant to the President during the tenure of Judith Rodin, the first female president of an Ivy League institution; and at Temple University, where he held the title of Assistant Dean and lead the development program at the Fox School of Business. Before entering higher education, Michael served as Legislative and Press Assistant to the late Congressman Tom Lantos, the only survivor of the Holocaust ever elected to Congress. Michael is a graduate of the University of Pennsylvania, where he earned a Bachelor’s degree in Communications and a Master’s degree in Public Administration. Prof. Dr. Matthias von Herrath, MD is the Scientific Director of the Diabetes Research Institute (DRI) and Stacy Joy Goodman Chair at the University of Miami School of Medicine ( https://med.miami.edu/faculty/matthias-georg-von-herrath ) where he is leading the DRI mission to conduct and accelerate research to delay, prevent and ultimately find a cure for type 1 diabetes.  He is widely recognized for his groundbreaking work in understanding the molecular mechanisms of T1D, an autoimmune disease in which the body’s immune system attacks and destroys insulin-producing beta cells in the pancreas, and developing novel therapies for this disease. Prof. Dr. von Herrath served as a Professor and Director for the Type 1 Diabetes Research Center at La Jolla Institute for Allergy and Immunology, and also currently serves as Vice President and Senior Medical Officer at Novo Nordisk, a global healthcare company, where he is responsible for overseeing the company’s research and development efforts in diabetes care.Prof. Dr. von Herrath earned his medical degree in 1988 from Freiburg Medical School, where he also completed a Ph.D. equivalent thesis on biochemistry. His postdoctoral training included an intensive care residency at Diakonie Hospital, Freiburg.#DiabetesResearchInstituteFoundation #T1D #Insulin #IsletCellTransplant #Regeneration #Immunomodulation #Immunoregulation #Autoimmune #UniversityOfMiami #Philanthropy #NovoNordisk #Instacart  #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster Support the show

Send us Fan MailDr. Legena Henry, Ph.D. is a Lecturer for Renewable Energy at University of the West Indies, Cave Hill Campus, Barbados ( https://www.cavehill.uwi.edu/fst/cmp/faculty-and-staff/academic-staff/physics/legena-henry.aspx ) with research specializing in Renewable Energy, Ocean Engineering Analysis, Ocean Wave Statistics, Marine Hydrodynamics, and Applied Mechanics. Dr. Henry is also the CEO and Founder of Rum and Sargassum Inc. ( https://rumandsargassum.com/ ), a novel transportation biofuel company in Barbados where her research has been translated and focuses on sustainably generating usable power output from natural resources of the Caribbean Sea, such as Sargassum seaweed and ocean waves.Dr. Henry completed her B.Sc. in Mechanical Engineering at Howard University, her M.Sc. in Ocean Engineering at the Center for Ocean Engineering at Massachusetts Institute of Technology (MIT), and completed her Ph.D. research in mechanical engineering at the University of the West Indies, St Augustine campus. Dr. Henry also currently serves on the MIT Educational Council. Important Episode Link - Experimental Evidence on the Use of Biomethane from Rum Distillery Waste and Sargassum Seaweed as an Alternative Fuel for Transportation in Barbados – 2021 – Interamerican Development Bank -https://publications.iadb.org/en/experimental-evidence-use-biomethane-rum-distillery-waste-and-sargassum-seaweed-alternative-fuel#LegenaHenry #Sargassum #Biofuel #Biomethane #CNG #CompressedNaturalGas #Rum #RenewableEnergy #UniversityOfTheWestIndies #Barbados #PrimeMinister #MiaMottley  #OceanEngineering #WaveStatistics #MarineHydrodynamics #AppliedMechanics  #Nature #Biodiversity #Environment #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast  #STEM #Innovation #Technology #Science #ResearchSupport the show